The stock’s rise followed FDA Commissioner Marty Makary’s warning against companies marketing illegal copycat drugs.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Eli Lilly Stock Has Over 20% Upside, Analysts Say: Retail Seeks Pharma 'Safe Haven' As FDA Targets GLP-1 Copycats
The stock’s rise followed FDA Commissioner Marty Makary’s warning against companies marketing illegal copycat drugs.